The purpose of this study is to compare how PF-00734200 is adsorbed, distributed, broken down and eliminated by subjects with mild, moderate and severe kidney impairment, by subjects receiving chronic hemodialysis, and by subjects with normal kidney function. The removal rate of PF-00734200 by hemodialysis will be calculated. The safety and tolerability of PF-00734200 in subjects with various degrees of kidney function or undergoing chronic hemodialysis will be assessed.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
30
The drug is administered as a single dose of four 5-mg tablets
Pfizer Investigational Site
Miami, Florida, United States
Pfizer Investigational Site
Orlando, Florida, United States
Pfizer Investigational Site
Minneapolis, Minnesota, United States
Pfizer Investigational Site
Knoxville, Tennessee, United States
Area under the curve from time 0 until last observation (AUCtlast)
Time frame: 3-6 days
Maximum serum concentration (Cmax)
Time frame: 3-6 days
AUC extrapolated to infinity (AUCinf)
Time frame: 3-6 days
Time of Cmax (Tmax)
Time frame: 3-6 days
Half life (T1/2)
Time frame: 3-6 days
Renal clearance (CLr)
Time frame: 3-6 days
Hemodialysis clearance (CLd)
Time frame: 3 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.